Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi Of Japan Plans U.S. Focus On Metabolic Syndrome

This article was originally published in PharmAsia News

Executive Summary

Japan's Shionogi acquired U.S.-based Sciele Pharma last year to give the Japanese firm a way to market its metabolic syndrome products, Shionogi President Isao Teshirogi says. He said his company wants to move away from its focus on antibiotics and give more emphasis to its medicines such as Crestor (rosuvastatin), marketed by AstraZeneca outside of Japan. Although Shionogi expects to continue to rely on Crestor as a major revenue source, the company faces a need for other sources of profit when the drug loses patent protection beginning in 2016. Teshirogi said the Sciele acquisition gives Shionogi a chance to use the U.S. firm's 800 medical representatives to sell an obesity drug it is developing. (Click here for more - a subscription may be required

You may also be interested in...



Merck Is Counting On Keytruda To Establish Its Anti-TIGIT Drug

Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.

EU Unveils Ambitions To ‘Future-Proof’ Entire Drug Regulatory Framework

Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.

AdvaMed Throws Weight Behind Protestors In Ongoing US Demonstrations

AdvaMed CEO Scott Whitaker shared a letter he sent to member companies voicing support for the ongoing protests around the US against police brutality that were sparked after the killing of George Floyd. “While we continue our single-minded pursuit of medical breakthroughs to treat and cure disease, we must also have a single-minded focus on eradicating the disease of racism in this country and around the world,” Whitaker wrote.

UsernamePublicRestriction

Register

AG002833

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel